The APAC human papillomavirus (HPV) vaccine market is expected to grow from US$ 567.57 million in 2022 to US$ 826.34 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2022 to 2028.

For her doctoral dissertation, Senior Planning Officer Idil Hussein studied the intentions of Finnish parents in terms of ...

One of the most effective vaccines available was going to become more accessible—until RFK Jr. dismissed the CDC’s advisory committee.

Human papillomavirus (HPV) is the necessary cause of cervical cancer, which is the second most common cancer in women worldwide with over 493,000 new cases occurring in 2002. High vaccine efficacy ...

Human papillomavirus (HPV) vaccines have long been central to reducing the global incidence of HPV‐associated cancers and benign lesions. Traditional vaccines, based on virus‐like particles ...

I currently test for human papillomavirus (HPV) DNA as a marker for HPV infection. With the advent of the HPV vaccine, how will clinicians be able to ...

National Cancer Registry reports an estimated 641 cases of new HPV-associated cancers diagnosed and 196 cancer deaths every ...

The vaccine is offered each year to boys and girls aged 12 to 13 to help protect them against catching the infection which causes nearly all cervical cancers and is linked to mout ...

National rates of human papillomavirus (HPV) vaccination remain below national benchmarks. 1 The Advisory Committee on Immunization Practices (ACIP) of the CDC has recommended the HPV vaccine ...

Effectiveness of the quadrivalent human papillomavirus (QHPV) vaccine against cervical dysplasia has not been estimated using population-based individual level data. We assessed the vaccine ...